We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Broad Institute & Calico Collaborate

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Broad Institute & Calico Collaborate"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

The Broad Institute of MIT and Harvard has entered into a partnership with Calico around the biology and genetics of aging and early-stage drug discovery. The partnership will support several efforts at the Broad to advance the understanding of age-related diseases and to propel the translation of these findings into new therapeutics.

Calico is the Google-backed life sciences company led by Arthur D. Levinson, Ph.D. (former Chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). As part of the collaboration, the Broad Institute will pursue shared goals with Calico by leveraging the Institute's deep genetics and biology expertise and novel drug-discovery tools.

"We are thrilled to be partnering on discovery and therapeutics projects with the extraordinary scientific team at Calico," said Eric Lander, President and Director of the Broad Institute. "The combination of our genetics, biology and chemistry expertise with Calico's therapeutics expertise will accelerate progress on important problems."

"This alliance is a key part of Calico's strategy to bring the best cutting-edge science to bear on problems of aging. The Broad Institute is one of the nation's preeminent research organizations whose outstanding research has repeatedly revealed fundamental mechanisms of the biology and genetics of disease," said Art Levinson, Chief Executive Officer of Calico.

"Broad scientists have led the way in describing the genetics underlying many of the common diseases of aging, including heart disease, diabetes, and cancer, and we look forward to collaborating with them. We are very excited by the opportunity to apply their insights to develop new medicines for patients with these devastating diseases," commented Hal Barron, President of Research and Development at Calico.